Lixte Biotechnology Holdings, Inc. reported that the interim analysis of its Phase Ib/II study combining the PP2A inhibitor LB‑100 with the PD‑1 blocker dostarlimab produced the first efficacy signal in ovarian clear‑cell carcinoma, a rare and aggressive subtype with limited treatment options.
The study enrolled 21 patients, all of whom were treated, and 20 were evaluable for efficacy. Median overall‑survival probability was 0.84 at 6 months and 0.69 at 12 months, while the disease‑control rate reached 40 %. These figures represent a meaningful clinical benefit in a population that historically has few effective therapies.
Chief Scientific Officer Bas van der Baan said, "The findings being presented provide new hope for patients with ovarian cancer, a disease that thus far has limited therapeutic options. LIXTE's proprietary compound, LB‑100, combined with GSK's anti‑PD1 drug Dostarlimab, has shown an acceptable safety profile. All 21 planned participants in the trial have been enrolled, and 20 were evaluated for efficacy in this interim analysis. Based on those favorable results, an additional cohort of 21 patients with a higher exposure to LB‑100 is in the process of enrolling." The company’s decision to expand the cohort underscores confidence in the preliminary data and signals intent to accelerate development.
Lixte’s broader strategy positions LB‑100 as a first‑in‑class enhancer of chemotherapy and immunotherapy across several solid tumors, including metastatic colon cancer and soft‑tissue sarcoma. The positive interim results in ovarian clear‑cell carcinoma strengthen the case for further investment in the compound and may broaden its clinical development portfolio. The company’s recent acquisition of Liora Technologies, a developer of proton‑therapy systems, also reflects a complementary push toward integrated drug‑and‑device solutions, potentially creating new revenue streams and reinforcing its competitive moat.
No market‑reaction data are available at this time, but the clinical milestone is expected to influence investor perception of Lixte’s pipeline trajectory and therapeutic potential.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.